Blackfynn and Children’s Hospital of Philadelphia said they have expanded their relationship. Under the expanded relationship, Blackfynn’s Data Platform will be used by CHOP and the Children’s Brain Tumor Tissue Consortium to bring together complex non-identifiable patient data for collaboration and analysis, thereby accelerating translational discovery toward treatments for brain cancer in children.
Blackfynn and CHOP began their relationship focused on pathology data one year ago. The expanded relationship will allow ongoing access to the Blackfynn Data Platform for CHOP and CBTTC members to conduct research across non-identifiable patient data, including pathology, imaging, genomics, EEG, clinical and other data. The ability to integrate and conduct analyses across all relevant data together is crucial to identifying meaningful patterns in treatment and disease.
Blackfynn is a privately held life sciences company focused on the development of a data platform to enable integration and analytics of complex, multimodal research and clinical data to enable better therapeutics and clinical care for patients with
neurologic disease.
